PVLA supply chain intelligence for Palvella Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Palvella Therapeutics, Inc. (PVLA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-MANUFACTURING-ORGANIZATIONS | CONTRACT-MANUFACTURING-ORGANIZATIONS | 92% | The Company is dependent on contract manufacturing organizations ("CMOs") to supply products for research and development of its product candidates, including pre-clinical and clinical studies, and f… |
| NEMERA-LE-TR-PORT-SAS | NEMERA-LE-TR-PORT-SAS | 92% | we have an agreement with Nemera Le Tréport SAS ("Nemera") for the supply of pumps we use to deliver QTORIN rapamycin |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from LGND g… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from LGNZZ graph: R Holders $ ( ) $ ( ) Supplemental cash flow disclosures: Purchases of pro… |
| ORANY | ORANY | 72% | ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from PVLA graph: ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by el… |
| RLAY | Relay Therapeutics, Inc. | 72% | ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment … |
| RLAY | Relay Therapeutics, Inc. | 72% | Reciprocal relationship from RLAY graph: Reciprocal relationship from PVLA graph: ting approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eli… |
| TARA | Protara Therapeutics, Inc. | 72% | Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from TARA g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a sum… |
| ORANY | ORANY | 72% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| RLAY | Relay Therapeutics, Inc. | 72% | Reciprocal relationship from RLAY graph: Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summ… |
| RLAY | Relay Therapeutics, Inc. | 72% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| TARA | Protara Therapeutics, Inc. | 72% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| TARA | Protara Therapeutics, Inc. | 72% | Reciprocal relationship from TARA graph: Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summ… |
| COMPANY-POLO-MERGER-SUB-INC | COMPANY-POLO-MERGER-SUB-INC | 62% | ived written feedback from the FDA in the first quarter of 2026 on the proposed design of a Phase 2 study to evaluate QTORIN pitavastatin for the treatment of DSAP. Trial initiation is anticipated in… |
| KAKEN-PHARMACEUTICAL-CO-LTD-NOBELPHARMA-CO-LTD | KAKEN-PHARMACEUTICAL-CO-LTD-NOBELPHARMA-CO-LTD | 62% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| LGND | Ligand Pharmaceuticals Incorporated | 62% | Reciprocal relationship from LGND graph: Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summ… |
| LIGAND-PHARMACEUTICALS-INC | LIGAND-PHARMACEUTICALS-INC | 62% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| NOVARTIS-PHARMACEUTICALS-PROTARA-THERAPEUTICS-IN | NOVARTIS-PHARMACEUTICALS-PROTARA-THERAPEUTICS-IN | 62% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| PIERIS-PHARMACEUTICALS-INC | PIERIS-PHARMACEUTICALS-INC | 62% | ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an investment in our common stock speculative or… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PVLA-DEBT | Debt stack $20.4M | 90% | Market cache reports total debt of $20.4M. |
| PVLA-DEBT-11960 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| PVLA-DEBT-11959 | Warrants outstanding: 123238 | 90% | xbrl warrant detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PVLA-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC | SUVRETTA CAPITAL MANAGEMENT, LLC | 90% | 13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 185 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| RLAY | Relay Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| LGNZZ | LIGAND PHARMACEUTICALS INC | 100.00 | 1 | ['supplier'] |
| TARA | Protara Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BFRGW | BullFrog AI Holdings, Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| BSX | Boston Scientific Corporation | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| DARE | Daré Bioscience, Inc. | 50.00 | 2 | |
| CINGW | Cingulate Inc. | 50.00 | 2 | |
| BFRIW | Biofrontera Inc. | 50.00 | 2 | |
| EPDU | ENTERPRISE PRODUCTS PARTNERS L.P. | 50.00 | 2 | |
| D | Dominion Energy, Inc. | 50.00 | 2 |